Literature DB >> 11463346

Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein.

J Eidenmüller1, T Fath, T Maas, M Pool, E Sontag, R Brandt.   

Abstract

The microtubule-associated tau proteins represent a family of closely related phosphoproteins that become enriched in the axons during brain development. In Alzheimer's disease (AD), tau aggregates somatodendritically in paired helical filaments in a hyperphosphorylated form. Most of the sites that are phosphorylated to a high extent in paired helical filament tau are clustered in the proline-rich region (P-region; residues 172--251) and the C-terminal tail region (C-region; residues 368--441) that flank tau's microtubule-binding repeats. This might point to a role of a region-specific phosphorylation cluster for the pathogenesis of AD. To determine the functional consequences of such modifications, mutated tau proteins were produced in which a P- or C-region-specific phosphorylation cluster was simulated by replacement of serine/threonine residues with glutamate. We show that a phosphorylation-mimicking glutamate cluster in the P-region is sufficient to block microtubule assembly and to inhibit tau's interaction with the dominant brain phosphatase protein phosphatase 2A isoform AB alpha C. P-region-specific mutations also decrease tau aggregation into filaments and decrease tau's process-inducing activity in a cellular transfection model. In contrast, a phosphorylation-mimicking glutamate cluster in the C-region is neutral with regard to these activities. A glutamate cluster in both the P- and C-regions induces the formation of SDS-resistant conformational domains in tau and suppresses tau's interaction with the neural membrane cortex. The results indicate that modifications in the proline-rich region are sufficient to induce the functional deficiencies of tau that have been observed in AD. They suggest that phosphorylation of the proline-rich region has a crucial role in mediating tau-related changes during disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11463346      PMCID: PMC1222005          DOI: 10.1042/0264-6021:3570759

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  41 in total

1.  Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly.

Authors:  D B Evans; K B Rank; K Bhattacharya; D R Thomsen; M E Gurney; S K Sharma
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

2.  Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments.

Authors:  T Maas; J Eidenmüller; R Brandt
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

Review 3.  Staging of Alzheimer's disease-related neurofibrillary changes.

Authors:  H Braak; E Braak
Journal:  Neurobiol Aging       Date:  1995 May-Jun       Impact factor: 4.673

4.  Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau.

Authors:  E S Matsuo; R W Shin; M L Billingsley; A Van deVoorde; M O'Connor; J Q Trojanowski; V M Lee
Journal:  Neuron       Date:  1994-10       Impact factor: 17.173

5.  Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration.

Authors:  G N Patrick; L Zukerberg; M Nikolic; S de la Monte; P Dikkes; L H Tsai
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

6.  Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17.

Authors:  M Hutton; C L Lendon; P Rizzu; M Baker; S Froelich; H Houlden; S Pickering-Brown; S Chakraverty; A Isaacs; A Grover; J Hackett; J Adamson; S Lincoln; D Dickson; P Davies; R C Petersen; M Stevens; E de Graaff; E Wauters; J van Baren; M Hillebrand; M Joosse; J M Kwon; P Nowotny; L K Che; J Norton; J C Morris; L A Reed; J Trojanowski; H Basun; L Lannfelt; M Neystat; S Fahn; F Dark; T Tannenberg; P R Dodd; N Hayward; J B Kwok; P R Schofield; A Andreadis; J Snowden; D Craufurd; D Neary; F Owen; B A Oostra; J Hardy; A Goate; J van Swieten; D Mann; T Lynch; P Heutink
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

7.  Proline-directed and non-proline-directed phosphorylation of PHF-tau.

Authors:  M Morishima-Kawashima; M Hasegawa; K Takio; M Suzuki; H Yoshida; K Titani; Y Ihara
Journal:  J Biol Chem       Date:  1995-01-13       Impact factor: 5.157

8.  Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein.

Authors:  M Goedert; R Jakes; R A Crowther; P Cohen; E Vanmechelen; M Vandermeeren; P Cras
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

9.  Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404.

Authors:  L Otvos; L Feiner; E Lang; G I Szendrei; M Goedert; V M Lee
Journal:  J Neurosci Res       Date:  1994-12-15       Impact factor: 4.164

10.  Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain.

Authors:  R Brandt; J Léger; G Lee
Journal:  J Cell Biol       Date:  1995-12       Impact factor: 10.539

View more
  43 in total

1.  The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies.

Authors:  Jean-Marie Sontag; Viyada Nunbhakdi-Craig; Charles L White; Shelley Halpain; Estelle Sontag
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

2.  Tyrosine nitration within the proline-rich region of Tau in Alzheimer's disease.

Authors:  Juan F Reyes; Yifan Fu; Laurel Vana; Nicholas M Kanaan; Lester I Binder
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

3.  Pseudophosphorylation of tau protein directly modulates its aggregation kinetics.

Authors:  Edward Chang; Sohee Kim; Kelsey N Schafer; Jeff Kuret
Journal:  Biochim Biophys Acta       Date:  2010-10-23

4.  Combinatorial Tau pseudophosphorylation: markedly different regulatory effects on microtubule assembly and dynamic instability than the sum of the individual parts.

Authors:  Erkan Kiris; Donovan Ventimiglia; Mehmet E Sargin; Michelle R Gaylord; Alphan Altinok; Kenneth Rose; B S Manjunath; Mary Ann Jordan; Leslie Wilson; Stuart C Feinstein
Journal:  J Biol Chem       Date:  2011-02-02       Impact factor: 5.157

Review 5.  Immunotherapeutic approaches for Alzheimer's disease.

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Neuron       Date:  2015-03-18       Impact factor: 17.173

Review 6.  Immunotherapy for Alzheimer's disease.

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Biochem Pharmacol       Date:  2014-01-09       Impact factor: 5.858

7.  The Rho kinase inhibitor fasudil attenuates Aβ1-42-induced apoptosis via the ASK1/JNK signal pathway in primary cultures of hippocampal neurons.

Authors:  Ye Gao; Yuqing Yan; Qingli Fang; Nianping Zhang; Gajendra Kumar; Jihong Zhang; Li-Juan Song; Jiezhong Yu; Linhu Zhao; Han-Ting Zhang; Cun-Gen Ma
Journal:  Metab Brain Dis       Date:  2019-09-03       Impact factor: 3.584

Review 8.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

9.  Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau.

Authors:  Christian Tackenberg; Roland Brandt
Journal:  J Neurosci       Date:  2009-11-18       Impact factor: 6.167

10.  Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.

Authors:  Qian Sun; T Chris Gamblin
Journal:  Biochemistry       Date:  2009-06-30       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.